<DOC>
	<DOC>NCT02323022</DOC>
	<brief_summary>The purpose of this study is to compare the clinical efficacy and safety of IAC regimen and IA regimen as induction chemotherapy for initial diagnosed AML patients. 840 cases are supposed to recruited in 3 years.</brief_summary>
	<brief_title>Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>Initially diagnosed as AML (except APL) Aged between 18 and 60 year old Eastern Cooperative Oncology Group (ECOG) score no more than 3 Informed consent file (ICF) signed AML secondary to chronic leukemia and myeloproliferative disease (MPD) APL With underlying malignancies except AML Uncontrolled severe infection Intolerant to chemotherapy organically including: Heart failure: ejection fraction (EF) less than 30%, and New York Heart Association (NYHA) grading high than Grade II Liver and kidney dysfunction: serum bilirubin≥2mg/dl, AST≥2.5*upper limit of normal (ULN), serum creatine≥2.5mg/dl Refuse to participate the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>AML</keyword>
	<keyword>cladribine</keyword>
	<keyword>induction therapy</keyword>
</DOC>